

Data Safety Monitoring Board Communication

Date: 15 Mar 2016

TO: TIRCON2012V1 study Investigators

FROM: Dr. Anna Rozova, Director, Medical Safety, ApoPharma Inc.

RE: Clinical study protocol, TIRCON2012V1: A randomized, double-blind, placebo-controlled trial of deferiprone in patients with pantothenate-kinase associated neurodegeneration (PKAN)

DSMB safety review meeting of 03 Mar 2016

The sixth interim review meeting of the independent Data Safety Monitoring Board (DSMB) for the clinical study, TIRCON2012V1, was held on 03 Mar 2016.

The meeting was scheduled and held according to the planned periodic review of safety data. The review encompassed the safety data collected from the beginning of the study until the cut-off period of 09 Jan 2016 and any late-breaking safety information received between the cut-off point and the date of the meeting.

The DSMB reviewed the above-referenced data. The DSMB did not identify any issues requiring premature unblinding, suspension or termination of the study, and recommended the continuation of the study without modification.

The next planned interim review meeting will be in Aug 2016.